TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
TCR2 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: TCR2 Therapeutics Reports Fourth Quarter And Full-Year 2022 Financial Results
TCR2 Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Tcr2 Therapeutics Inc - Has About $1.2 Million Of Restricted Cash As Certificates Of Deposits For Facility Leases Held At Svb
U.S. RESEARCH ROUNDUP-Etsy, Qualtrics International, Tcr2 Therapeutics
U.S. STOCKS ON THE MOVE-CrowdStrike, Dentsply Sirona, Qualtrics
TCR2 Therapeutics surges on Adaptimmune buyout
U.S. STOCKS ON THE MOVE-Tesla, BridgeBio, Unicycive Therapeutics, Allbirds
TCR2 Therapeutics surges on Adaptimmune buyout
U.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
TCR2 Therapeutics surges on Adaptimmune buyout deal
Brief: Adaptimmune & Tcr² Therapeutics Announce Strategic Combination
U.S. RESEARCH ROUNDUP- Humana, JP Morgan, Voya Financial
Brief: TCR2 Therapeutics To Be Streamlined With About 40% Reduction In Workforce
TCR2 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary